Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer

Marco Montanari1, Francesco Fabbri2, Ermanno Rondini3, Giovanni Luca Frassinetti4, Rodolfo Mattioli5, Silvia Carloni2, Emanuela Scarpi4, Wainer Zoli2, Dino Amadori4, and Giorgio Cruciani1

1Oncology Unit, Santa Maria delle Croci Hospital, Ravenna; 2Biosciences Laboratory, IRCCS, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (FC); 3Oncology Unit, Santa Maria Nuova Hospital, Reggio Emilia; 4Department of Medical Oncology, IRCCS; 5Oncology Unit, Santa Croce Hospital, Fano, Italy

ABSTRACT

Aims and background. Non-pegylated liposomal doxorubicin (NPLD) (Myocet) has shown marked *in vitro* activity in castration-resistant prostate cancer (CRPC) and also in docetaxel-resistant cells, higher than that shown by pegylated liposomal doxorubicin. Its activity would seem to be due to a high intracellular drug concentration and induction of Golgi-dependent apoptosis. On the basis of these results, a clinical study was designed to assess the activity of NPLD and low-dose prednisone in second-line therapy.

Methods. Fifty-four patients were enrolled and evaluated. Eligibility criteria were histologically confirmed CRPC, PSA >20 ng/mL or measurable lesions according to the RECIST criteria, previous docetaxel-based chemotherapy, and adequate cardiac function. Patients were treated with weekly intravenous NPLD 25 mg/m² and daily prednisone 10 mg until progression.

Results. Median patient age was 69 years (range, 52-83) and median baseline PSA concentration was 120 ng/mL (range, 5.35-4350). Sixteen (29.6%) patients had measurable lesions. Objective or PSA responses (>50% reduction) were observed in 8 (14.8%) patients. The median time to progression was 2.8 months and the median overall survival was 11.3 months. Toxicity was generally mild (grade 1-2) and infrequent, with grade 3-4 neutropenia in 12.9% of cases. Grade 3 nonhematological toxicities included nausea in 2 patients (3.7%) and fatigue and stomatitis in 1 case (1.9%). No drug-related serious adverse events were reported.

Conclusions. Weekly administration of NPLD is a well tolerated treatment with proven albeit limited activity.

Key words: castration-resistant prostate cancer, liposomal anthracyclines, chemotherapy, translational research.

Acknowledgments: The authors wish to thank the following clinical investigators who participated in this trial: A Cariello, F Carrozza, C Casanova, C Dazzi, E Freier, S Iacovelli, M Leoni, M Lolli, S Luzi Fedeli, V Mazza, L Matteucci, F Monduzzi, G Papiani, MC Quarta, A Ravaoli, G Scambia, A Tienghi, D Turci, A Verlicchi.

Financial disclosure: Myocet® was provided by Cephalon because it is not registered for use in prostate cancer. The study was not further supported.

Authors’ disclosures of potential conflicts of interest: The authors indicated no potential conflicts of interest.

Correspondence to: Marco Montanari, MD, Oncology Unit, Santa Maria delle Croci Hospital, Viale Randi 5, Ravenna, Italy.
Tel +39-0544-285956; email marcomontanarimail@libero.it

Received February 16, 2012; accepted August 1, 2012.